{"disease":{"id":"severe-hemophilia-a","name":"severe hemophilia a"},"drugs":{"marketed":[{"drug_id":"gbt021601","indication_name":"Treatment of adult patients with severe hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gbt021601","generic_name":"gbt021601","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT06938542","title":"Palliative Care Needs of Children With Rare Diseases and Their Families","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":480,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT02172950","title":"An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT05181618","title":"A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":136,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06142552","title":"Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Jiangsu Gensciences lnc.","has_results":false},{"nct_id":"NCT06136507","title":"Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":76,"lead_sponsor_name":"Jiangsu Gensciences lnc.","has_results":false},{"nct_id":"NCT04431726","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT00323856","title":"Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Grifols Biologicals, LLC","has_results":true},{"nct_id":"NCT06137092","title":"rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"AryoGen Pharmed Co.","has_results":false},{"nct_id":"NCT05981274","title":"A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)","phase":"","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tri-Service General Hospital","has_results":false},{"nct_id":"NCT04046848","title":"Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Octapharma","has_results":true},{"nct_id":"NCT07446010","title":"Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04754997","title":"Effect of Exercise in Pediatric Hemophilia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Hasan Kalyoncu University","has_results":false},{"nct_id":"NCT06703606","title":"A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06155955","title":"Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT05265286","title":"A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Jiangsu Gensciences lnc.","has_results":false},{"nct_id":"NCT05281185","title":"Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT04864743","title":"A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Jiangsu Gensciences lnc.","has_results":false},{"nct_id":"NCT03376516","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Octapharma","has_results":true},{"nct_id":"NCT05127681","title":"Bone Microarchitecture in Men With Hemophilia","phase":"NA","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04817462","title":"Liver Biopsy In Haemophilia Gene Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT01051076","title":"Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01051544","title":"Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}